Medikamentös induzierte Immunhämolysen

Die medikamentös induzierte Immunhämolyse stellt eine seltene, häufig fulminant und immer wieder letal verlaufende Sonderform der autoimmunhämolytischen Anämie dar. Sie ist wenig bekannt und wird häufig übersehen. Dieser Beitrag stellt die Besonderheiten des Krankheitsbildes inkl. wesentlicher Aspekte zur Pathogenese, Klinik, Diagnostik und Therapie vor und zeigt, welche Medikamente häufig eine Immunhämolyse auslösen können.

Abstract

Drug induced immune hemolytic anemia (DIIHA) is rare and often associated with severe hemolytic anemia and even death. It is not well known and likely under-diagnosed. DIIHA may be caused by drug-independent autoantibodies (aab) indistinguishable from idopathic warm autoantibodies causing autoimmune hemolytic anemia, or by drug-dependent antibodies (ddab). The latter only react in the presence of the drug and can cause acute and severe intravascular hemolysis. ddab usually show a positive direct antiglobulin test (DAT) and a negative eluate. However, specialized reference laboratories are often required to perform the serological tests to confirm the diagnosis. The most common drugs to cause ddab are antibiotics (mainly piperacillin and cephalosporines), non-steroidal drugs (diclofenac) and platinum-based anticancer drugs. Stopping the drug is the first and most important approach to therapy.

This paper presents the special features of the clinical picture including essential aspects of pathogenesis, clinic, diagnostics and therapy of drug induced immune hemolytic anemia.

Schlüsselwörter

medikamentös induzierte Hämolysen - medikamentenabhängige Antikörper - intravasale Hämolyse - erythrozytäre Autoantikörper

Key words

drug-induced hemolysis - drug-dependent antibodies - intravascular hemolysis - autoantibodies

Publikationsverlauf

Artikel online veröffentlicht:
11. Mai 2023

• Literatur

• 1 Garbe E, Andersohn F, Bronder E. et al. Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study. Br J Haematol 2011; 154: 644-653
• 2 Garratty G. Drug induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009; 73-79 10.1182/asheducation-2009.1.73
• 3 Salama A, Mayer B. Diagnostic pitfalls of drug induced immune hemolytic anemia. Immunohematology 2014; 30: 80-84
• 4 Mueller-Eckhardt C, Salama A. Drug induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev 1990; 4: 69-77
• 5 Salama A, Mueller-Eckhardt C. Immune-mediated blood cell dyscrasias related to drugs. Semin Hematol 1992; 29: 54-63
• 6 Arndt PA. Drug induced immune hemolytic anemia: the last 30 years of changes. Immunohematology 2014; 30: 44-54
• 7 Petz L, Garratty G. Drug induced immune hemolytic anemia. In: Immune hemolytic anemias. 2nd. Ed. Churchill Livingstone 2004; 261-317
• 8 Ackroyd JF. The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedormid. Clin Sci 1949; 7: 249-285
• 9 Muirhead EE, Halden ER, Groves M. Drug-dependent Coombs (antiglobulin) test and anemia; observations on quinine and acetophenetidin (phenacetin). AMA Arch Intern Med 1958; 101: 87-96
• 10 Salama A. Drug induced immune hemolytic anemia. Expert Opin Drug Saf 2009; 8: 73-79
• 11 Petz LD. Drug induced autoimmune hemolytic anemia. Transfus Med Rev 1993; 7: 242-254
• 12 Worlledge SM. Autoantibody formation associated with methyldopa (aldomet) therapy. Br J Haematol 1969; 16: 5-8
• 13 Carstairs KC, Breckenridge A, Dollery CT. et al. Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet 1966; 2: 133-135
• 14 Tertian G, Cartron J, Bayle C. et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38: 359-360
• 15 Myint H, Copplestone JA, Orchard J. et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-344
• 16 Fattizzo B, Rampi N, Barcellini W. Hematological and extra-hematological autoimmune complications after checkpoint inhibitors. Pharmaceuticals 2022; 15: 557
• 17 Salama A, Kroll H, Wittmann G. et al. Diclofenac induced immune haemolytic anaemia: simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies. Br J Haematol 1996; 95: 640-644
• 18 Snapper I, Marks D, Schwartz L. et al. Hemolytic anemia secondary to mesantoin. Ann Intern Med 1953; 39: 619-623
• 19 Garratty G, Arndt PA. Drugs that have been shown to cause drug induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 2014; 30: 66-79
• 20 Mayer B, Bartolmäs T, Yürek S. et al. Variability of findings in drug induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother 2015; 42: 333-339
• 21 Mayer B, Leo A, Herziger A. et al. Intravascular immune hemolysis caused by the contrast medium iomeprol. Transfusion 2013; 53: 2141-2144
• 22 Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug induced immune hemolytic anemia. Transfusion 2012; 52: 602-612
• 23 Mayer B, Yürek S, Salama A. Piperacillin induced immune hemolysis: new cases and a concise review of the literature. Transfusion 2010; 50: 1135-1138
• 24 Quillen K, Lane C, Hu E. et al. Prevalence of ceftriaxone induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J 2008; 27: 357-358
• 25 Roehmel J, Specht P, Staab D. et al. Risk of piperacillin induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. Transfusion 2019; 59: 3746-3754
• 26 Ries CA, Rosenbaum TJ, Garratty G. et al. Penicillin induced immune hemolytic anemia. Occurrence of massive intravascular hemolysis. JAMA 1975; 233: 432-435
• 27 Ahrens N, Genth R, Kiesewetter H. et al. Misdiagnosis in patients with diclofenac induced hemolysis: new cases and a concise review. Am J Hematol 2006; 81: 128-131
• 28 Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 2010; 24: 143-150
• 29 Northrop MS, Agarwal HS. Ceftriaxone induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol 2015; 37: e63-e66
• 30 Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf 2012; 11: 635-642
• 31 Johnson ST, Fueger JT, Gottschall JL. One center’s experience: the serology and drugs associated with drug induced immune hemolytic anemia--a new paradigm. Transfusion 2007; 47: 697-702
• 32 Pierce A, Nester T. Scientists ECotAoCLPa. Pathology consultation on drug induced hemolytic anemia. Am J Clin Pathol 2011; 136: 7-12
• 33 Leger RM, Arndt PA, Garratty G. How we investigate drug induced immune hemolytic anemia. Immunohematology 2014; 30: 85-94
• 34 Leger RM, Arndt PA, Garratty G. Serological studies of piperacillin antibodies. Transfusion 2008; 48: 2429-2434
• 35 Hill QA, Stamps R, Massey E. et al. Guidelines on the management of drug induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 2017; 177: 208-220
• 36 Vehapoğlu A, Göknar N, Tuna R. et al. Ceftriaxone induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin. Turk J Pediatr 2016; 58: 216-219
• 37 Arndt P, Garratty G, Isaak E. et al. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug induced nonimmunologic protein adsorption. Transfusion 2009; 49: 711-718